AI Drug Discovery industry news
Never miss what your AI Drug Discovery competitors ship.
42 updates from 11 AI Drug Discovery companies this past week. We read them all so you don't have to.
✓ Start tracking competitors within minutes
✓ Receive updates on their activities
✓ No credit card required
150,000+ companies tracked · 137M URLs counted · Tracking since 2025 · GDPR compliant · EU infrastructure
This page collects AI Drug Discovery industry news from the companies themselves. Parano.ai tracks 12 companies in this market, including AbCellera, Absci, Formation Bio, Generate:Biomedicines, Genesis Molecular AI and 7 more, and turns what they publish and change into digestible intel reports, battlecards and sales enablement assets.
- Updates in the latest digest
- 42from 11 companies
- Latest digest covers
- Oct 15 to Oct 22, 2026
Most active in the last 7 days, mostly event pages and product pages:
Insilico Medicine8 updates
Xaira4 updates
Generate:Biomedicines3 updates
Every summary links to its public source.
AI Drug Discovery news this week
Oct 15 – Oct 22, 2026
This is last week's digest for AI Drug Discovery. Get one built for your actual competitors →
Executive Summary
Schrödinger and Xaira have both introduced agentic AI platforms, Bunsen and X-Scientist respectively, designed to automate complex scientific workflows and adapt computational tasks to specific research goals.[1][2]- Insilico Medicine is promoting its MMAI KINOME model, which allows researchers to predict inhibitory potency across 67 kinase targets via the MMAI Playground.[3]
Recursion announced clinical progress for its REC-4881 and REC-1245 programs, marking a milestone in its Sanofi partnership, and secured a $200 million public offering to extend its cash runway to 2029.[4][5][6]- Insilico Medicine reached its first R&D milestone in its oncology collaboration with Servier, which has a total potential value of up to $888 million.[7]
Formation Bio shared details on Phyla, a context layer for causal biology that aggregates evidence from 27 biomedical sources, and highlighted an upcoming demonstration of Veeva Vault and Snowflake integration for AI-ready clinical data.[8][9]
Abcellera, Absci, and RelayTx reported various clinical and community engagement activities, including upcoming Phase 1/2 results for ABCL635, interim data for ABS-201, and participation in VASCAPA Day 2026.[10][11][12]
12 sources
- Schrodinger — Schrodinger Introduces Bunsen Agentic Co-Scientist for Adaptive Workflows
- Xaira — Xaira Introduces X-Scientist Agentic AI Platform for Drug Discovery
- Insilico — Insilico Medicine Promotes MMAI KINOME for Kinase Target Prediction
- Recursion — Recursion Announces Clinical Progress and $200 Million Offering
- Recursion — Recursion Announces Clinical Milestones and $200 Million Funding
- Recursion — Recursion Announces Clinical Progress and $200 Million Public Offering
- Insilico — Insilico Medicine Achieves First R&D Milestone in Servier Oncology Collaboration
- Formation Bio — Formation Bio Shares Phyla Causal Biology Context Layer
- Formation Bio — Formation Bio Amplifies Emily Ashby's Post on Veeva and Snowflake Integration
- Abcellera — Abcellera to Present ABCL635 Phase 1/2 Results at Menopause Society Meeting
- Absci — Absci Discusses ABS-201 Clinical Trial Progress and Mechanism
- Relaytx — RelayTx Attends VASCAPA Day 2026 in Belgium
Tracking 11 AI Drug Discovery vendors like this?
Tracking since 2025 · GDPR compliant · EU infrastructure
Latest AI Drug Discovery company updates
Generate:Biomedicines Shares Phase 1 Study Design for GB-4362
Xaira Launches X-Automate to Bring Agentic AI into the Lab
Schrödinger to Host Webinar on Bunsen Agentic Workflows
Tracking 11 AI Drug Discovery vendors like this?
Generate Biologics Shares Insights on CryoEM for Antibody Design
Insilico Medicine Launches inClinico Agent for Clinical Trial Prediction
Insilico Medicine Discusses AI and Drug Discovery at AI Everything Abu Dhabi
Xaira Showcases X-Automate Laboratory Automation System
Xaira Launches X-Scientist Agentic AI Platform for Drug Discovery
Generatebiomedicines to Participate in November Investor Conferences
Absci Deploys AMD Instinct™ MI300X Cluster for AI Drug Discovery
RelayTx Shares Preliminary Zovegalisib Results at PeDRA 2026
Recursion Explains Its Integrated DMTL Platform for Drug Discovery
Insilico Medicine Achieves First R&D Milestone in Servier Oncology Collaboration
Insilico Medicine to Present ISM6331 Human Data at ESMO 2026
Insilico Medicine Showcases Pharma.AI at Future Health Abu Dhabi
Insilico Medicine Shares Research on Garutadustat at IBD Innovate 2026
Insilico to Deliver Keynote at Colorectal Cancer Canada Conference
Xaira Introduces X-Scientist Agentic AI Platform for Drug Discovery
Schrodinger Introduces Bunsen Agentic Co-Scientist for Adaptive Workflows
BioXconomy Highlights Life Sciences Leaders for Black History Month
Insilico Medicine to Discuss AI-Driven IBD Barrier Therapies at IBD Innovate 2026
AI Drug Discovery companies we track
- AbCellera
- Absci
- Formation Bio
- Generate:Biomedicines
- Genesis Molecular AI
- Insilico Medicine
- Isomorphic Labs
- Recursion
- Relay Therapeutics
- Schrödinger
- Valo Health
- Xaira
Parano.ai · Industry news · AI-Powered Competitive Intelligence